 The study found that two doses of the adjuvant recombinant Zoster vaccine, RZV, administered early post-AUHCT-induced robust, persistent, and polyfunctional GE-specific immune responses in immunocompromised individuals, particularly autologous hematopoietic stem cell transplant, AUHCT, recipients. The study also found that vaccine efficacy against herpes Zoster, HZ, was high in non-Hodgkin B-cell lymphoma, NHBCL, patients despite the lower hormonal response. This article was authored by Edward A. Stadmore, Keith M. Sullivan, Mohammed Elidrissi, and others.